Shares of Synthetic Biologics (SYN) are up 65% so far in 2015 due to high expectations for its gastrointestinal drugs. The company’s CEO Jeffrey Riley said the company is on track to meet and maybe even raise those bars in the coming year. 'Our GI drugs are unique primarily because they are incredibly safe, there’s no off-target activity and they have a profound impact on the underlying cause of these problems for these particular patients,' said Riley. 'We are not treating the symptoms, we are treating the underlying causes.' Synthetic Biologics is a clinical stage biotech company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The company's Synthetic’s SYN-010 treatment is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). Synthetic Biologics recently finished a Phase II study of SYN-010 and plans to have a discussion with the FDA about the trials early in 2016. He said they have a second Phase II currently underway and plan to have that data for review by the middle of 2016.